Neither Xeomin nor Botox is categorically better than the other. Both contain the same active ingredient, botulinum toxin type A, and clinical studies consistently show they perform equally well when dosed at a 1:1 unit ratio. The real differences between them are structural, and those differences matter more for some patients than others.
The Core Difference: Accessory Proteins
Botox contains botulinum toxin bundled with a cluster of accessory proteins. These proteins surround the active toxin but have no therapeutic function. Xeomin strips all of those away during manufacturing, delivering only the 150-kilodalton neurotoxin itself. This is why Xeomin is sometimes called the “naked injectable.” The purification process removes every clostridial protein except the one that actually relaxes muscles.
In practical terms, this means you’re getting the same muscle-relaxing molecule with both products. The wrapping is just different.
Results, Onset, and Duration
Both products take roughly the same time to kick in, typically within a week, and both last three to six months before the effects wear off and muscles gradually regain movement. Clinical trials comparing the two for frown lines (glabellar lines) have found them therapeutically equivalent at a 1:1 conversion ratio, meaning 20 units of Xeomin produces the same effect as 20 units of Botox.
Some patients report that one product feels slightly different from the other in terms of how quickly results appear or how long they last, but controlled studies haven’t confirmed a consistent advantage for either. Individual variation in metabolism, muscle mass, and injection technique from your provider tend to matter more than the product label.
Why Antibody Resistance Matters
This is where Xeomin has a genuine, measurable edge for certain patients. Your immune system can develop antibodies against botulinum toxin over time, especially with repeated injections. Those accessory proteins in Botox are thought to increase the chance of triggering this immune response. When antibodies neutralize the toxin before it can work, treatments gradually stop being effective. This is called secondary treatment failure.
A 48-week study in Frontiers in Neurology tracked patients who had stopped responding to other botulinum toxin products (including Botox). After switching to Xeomin, antibody levels declined in about 40% of patients and held steady in another 32%. Only about 23% saw their antibody levels rise. More importantly, the patients showed significant clinical improvement even though they’d become resistant to their previous product.
For someone getting injections once or twice a year for cosmetic purposes, antibody resistance is unlikely to be a concern. But if you’re receiving higher doses more frequently for medical conditions like cervical dystonia or chronic spasticity, Xeomin’s lower protein load could help maintain effectiveness over years of treatment.
Precision and Spread
Xeomin has minimal spread after injection, meaning it tends to stay close to where it’s placed. Botox has a moderate diffusion pattern. In practice, both are considered precise compared to Dysport (a third botulinum toxin product known for wider spread). The slightly tighter diffusion of Xeomin can be an advantage in small, targeted areas where you don’t want the toxin affecting neighboring muscles. For broader areas, Botox’s moderate spread can actually work in its favor by covering more territory with fewer injection points.
Storage and Convenience
Xeomin is stable at room temperature for up to three years. Testing has shown no loss in quality even after storage at temperatures up to 40°C (104°F). Botox requires refrigeration. This distinction doesn’t directly affect your experience as a patient, but it does mean Xeomin is easier for clinics to store and transport, which can reduce the chance of improper handling compromising potency before it reaches your face.
Cost Comparison
Pricing for both products falls in the same range: roughly $8 to $35 per unit, plus any facility or administration fees your provider charges. Because the dosing ratio is 1:1, the total cost per session is comparable. Some clinics price Xeomin slightly lower since it’s less well-known and competes on value, but this varies widely by location and provider. Always ask about the per-unit cost rather than just the total price, so you can compare apples to apples.
FDA-Approved Uses
Botox holds the wider range of FDA approvals, covering cosmetic frown lines, crow’s feet, forehead lines, chronic migraine, overactive bladder, excessive sweating, and several spasticity conditions. Xeomin is approved for frown lines, cervical dystonia, blepharospasm (involuntary eyelid closure), upper limb spasticity in adults and some pediatric patients, and chronic drooling in patients two years and older.
If your treatment goal falls within Xeomin’s approved uses, the narrower approval list doesn’t matter. But for conditions like chronic migraine or excessive sweating, Botox remains the product with established FDA backing.
Which One Should You Choose
For most cosmetic patients getting treated a few times a year, the two products will feel nearly identical in results, duration, and cost. Your provider’s skill with injection placement will influence your outcome far more than which brand is in the syringe.
Xeomin becomes the stronger choice if you’ve noticed your Botox results fading faster over time (a possible sign of antibody development), if you need frequent or high-dose treatments for a medical condition, or if you prefer a formulation with fewer inactive proteins. Some patients also choose Xeomin simply because the idea of a “cleaner” product appeals to them, even if the clinical outcome is the same.
Botox makes more sense if you’re being treated for a condition outside Xeomin’s approved indications, or if you’ve been getting consistent, satisfying results and see no reason to switch. Providers also have decades of experience with Botox’s diffusion characteristics, which can matter for nuanced cosmetic work in areas like the forehead or around the eyes.